Champions Oncology Reports Q3 Net Loss and Sharp Adjusted EBITDA Decline Despite Strong Core Service Revenue Growth

summarizeSummary

Champions Oncology reported a net loss of $0.28 million and a substantial decline in Adjusted EBITDA to $0.57 million for Q3 fiscal 2026, primarily due to the absence of a prior-year data license transaction, though core study service revenue grew 32%.

check_boxKey Events

• Q3 Revenue Decline Driven by Prior-Year One-Time Event

  Total revenue for the third quarter of fiscal 2026 decreased 2.8% to $16.6 million, primarily due to the absence of a $4.5 million data license transaction recognized in the prior-year period.

• Significant Drop in Profitability

  The company reported a net loss of $0.28 million for the quarter, a substantial shift from a net income of $4.5 million in the prior-year period. Adjusted EBITDA also fell sharply to $0.57 million from $5.1 million year-over-year.

• Strong Core Study Service Revenue Growth

  Excluding the prior-year data license, study service revenue increased 32% year-over-year, reaching a record $16.6 million, driven by strong study execution and conversion of previously booked work.

• Increased Operating Expenses Impact Margins

  Cost of oncology revenue increased 33.5% due to higher outsourced lab service costs, contributing to a decline in oncology services margin to 47% from 61%. Research and development, sales and marketing, and general and administrative expenses also rose significantly due to strategic investments.

auto_awesomeAnalysis

Champions Oncology's third-quarter results show a significant deterioration in profitability, with a net loss and a substantial drop in Adjusted EBITDA compared to the prior year. While the overall revenue decline is attributed to the absence of a one-time data license transaction from the previous year, the core study service revenue demonstrated robust 32% growth. This indicates a mixed performance where the underlying business is expanding, but the company's overall financial metrics are negatively impacted by the comparison to a strong prior-year quarter that included a non-recurring high-margin event. Increased operating expenses, particularly in outsourced lab services, R&D, and sales & marketing, also contributed to the reduced profitability. Investors will need to weigh the strong underlying service growth against the significant decline in reported earnings and EBITDA, especially as the company trades near its 52-week low. Management's reiteration of full-year revenue growth and positive adjusted EBITDA provides some reassurance, supported by a healthy cash position and no debt.